Mainz Biomed NV (FRA:4TO) EBIT per Share : €-60.22 (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV EBIT per Share?

Mainz Biomed NV's EBIT per Share for the three months ended in Jun. 2024 was €0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €-60.22.

During the past 3 years, the average EBIT per Share Growth Rate was -278.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Mainz Biomed NV's EBIT per Share or its related term are showing as below:

FRA:4TO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -278 Med: -242.85 Max: -207.7
Current: -278

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Mainz Biomed NV was -207.70% per year. The lowest was -278.00% per year. And the median was -242.85% per year.

FRA:4TO's 3-Year EBIT Growth Rate is ranked worse than
99.42% of 172 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05 vs FRA:4TO: -278.00

Mainz Biomed NV's EBIT for the three months ended in Jun. 2024 was €0.00 Mil.

Mainz Biomed NV EBIT per Share Historical Data

The historical data trend for Mainz Biomed NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV EBIT per Share Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-2.32

-0.89

-55.81

-69.60

-57.56

Mainz Biomed NV Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial									-16.51	-19.61	-13.25	-10.85	-

Mainz Biomed NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Mainz Biomed NV's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.371	/	0.406
=	-57.56

Mainz Biomed NV's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0	/	0.559
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-60.22

Mainz Biomed NV (FRA:4TO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Mainz Biomed NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Mainz Biomed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (FRA:4TO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MYNZ:USA

Address

Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Mainz Biomed NV Headlines

No Headlines